Your browser doesn't support javascript.
loading
Causes of Death in Patients With Brain Metastases.
Schnurman, Zane; Mashiach, Elad; Link, Katherine E; Donahue, Bernadine; Sulman, Erik; Silverman, Joshua; Golfinos, John G; Oermann, Eric Karl; Kondziolka, Douglas.
Afiliação
  • Schnurman Z; Department of Neurosurgery, NYU Langone Health, New York , New York , USA.
  • Mashiach E; Department of Neurosurgery, NYU Langone Health, New York , New York , USA.
  • Link KE; Department of Neurosurgery, NYU Langone Health, New York , New York , USA.
  • Donahue B; Department of Radiation Oncology, NYU Langone Health, New York , New York , USA.
  • Sulman E; Department of Radiation Oncology, NYU Langone Health, New York , New York , USA.
  • Silverman J; Department of Radiation Oncology, NYU Langone Health, New York , New York , USA.
  • Golfinos JG; Department of Neurosurgery, NYU Langone Health, New York , New York , USA.
  • Oermann EK; Department of Neurosurgery, NYU Langone Health, New York , New York , USA.
  • Kondziolka D; Department of Neurosurgery, NYU Langone Health, New York , New York , USA.
Neurosurgery ; 93(5): 986-993, 2023 Nov 01.
Article em En | MEDLINE | ID: mdl-37255296
BACKGROUND AND OBJECTIVES: Advances in targeted therapies and wider application of stereotactic radiosurgery (SRS) have redefined outcomes of patients with brain metastases. Under modern treatment paradigms, there remains limited characterization of which aspects of disease drive demise and in what frequencies. This study aims to characterize the primary causes of terminal decline and evaluate differences in underlying intracranial tumor dynamics in patients with metastatic brain cancer. These fundamental details may help guide management, patient counseling, and research priorities. METHODS: Using NYUMets-Brain-the largest, longitudinal, real-world, open data set of patients with brain metastases-patients treated at New York University Langone Health between 2012 and 2021 with SRS were evaluated. A review of electronic health records allowed for the determination of a primary cause of death in patients who died during the study period. Causes were classified in mutually exclusive, but collectively exhaustive, categories. Multilevel models evaluated for differences in dynamics of intracranial tumors, including changes in volume and number. RESULTS: Of 439 patients with end-of-life data, 73.1% died secondary to systemic disease, 10.3% died secondary to central nervous system (CNS) disease, and 16.6% died because of other causes. CNS deaths were driven by acute increases in intracranial pressure (11%), development of focal neurological deficits (18%), treatment-resistant seizures (11%), and global decline driven by increased intracranial tumor burden (60%). Rate of influx of new intracranial tumors was almost twice as high in patients who died compared with those who survived ( P < .001), but there was no difference in rates of volume change per intracranial tumor ( P = .95). CONCLUSION: Most patients with brain metastases die secondary to systemic disease progression. For patients who die because of neurological disease, tumor dynamics and cause of death mechanisms indicate that the primary driver of decline for many may be unchecked systemic disease with unrelenting spread of new tumors to the CNS rather than failure of local growth control.
Assuntos

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Radiocirurgia Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Revista: Neurosurgery Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Radiocirurgia Tipo de estudo: Etiology_studies Limite: Humans Idioma: En Revista: Neurosurgery Ano de publicação: 2023 Tipo de documento: Article